canSAR 2024—an update to the public drug discovery knowledgebase
Nucleic Acids Research · 06.01.2025 · 53 (D1) · D1287-D1294
DOI: 10.1093/nar/gkae1050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 13.11.2024. Verfasst von Phillip W Gingrich und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine; Therapeutics Discovery Division; and The Institute for Data Science in Oncology; University of Texas MD Anderson Canc…. Hauptthemen laut MEDLINE: Drug Discovery, Knowledge Bases, Algorithms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anderson Institute for Data Science in Oncology, Cancer Prevention and Research Institute of Texas, The Lyda Hill Foundation.
Abstract (Originalsprache)
canSAR (https://cansar.ai) continues to serve as the largest publicly available platform for cancer-focused drug discovery and translational research. It integrates multidisciplinary data from disparate and otherwise siloed public data sources as well as data curated uniquely for canSAR. In addition, canSAR deploys a suite of curation and standardization tools together with AI algorithms to generate new knowledge from these integrated data to inform hypothesis generation. Here we report the latest updates to canSAR. As well as increasing available data, we provide enhancements to our algorithms to improve the offering to the user. Notably, our enhancements include a revised ligandability classifier leveraging Positive Unlabeled Learning that finds twice as many ligandable opportunities across the pocketome, and our revised chemical standardization pipeline and hierarchy better enables the aggregation of structurally related molecular records.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine; Therapeutics Discovery Division; and The Institute for Data Science in Oncology; University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Enterprise Development and Integration, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Centre for Cancer Drug Discovery, Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RP, UK.
ORCID-Profile: Phillip W Gingrich, Patrizio di Micco, Paul Workman, Bissan Al-Lazikani
Förderung
- Anderson Institute for Data Science in Oncology
- Cancer Prevention and Research Institute of Texas
- The Lyda Hill Foundation
- CRUK Programme
- Strategic Award, Infrastructure Award
- Brain Tumour Centre of Excellence
- Chordoma Foundation
- Mark Foundation
Zitieren
APA
Gingrich, P. W., Chitsazi, R., Biswas, A., Jiang, C., Zhao, L., Tym, J. E., Brammer, K. M., Li, J., Shu, Z., Maxwell, D. S., Tacy, J. A., Mica, I. L., Darkoh, M., di Micco, P., Russell, K. P., Workman, P., & Al-Lazikani, B. (2025). canSAR 2024—an update to the public drug discovery knowledgebase. Nucleic Acids Research, 53(D1), D1287-D1294. https://doi.org/10.1093/nar/gkae1050
Vancouver
Gingrich PW, Chitsazi R, Biswas A, Jiang C, Zhao L, Tym JE, et al. canSAR 2024—an update to the public drug discovery knowledgebase. Nucleic Acids Research. 2025;53(D1):D1287-D1294. doi:10.1093/nar/gkae1050
BibTeX
@article{Gingrich2025,
author = {Gingrich, Phillip W and Chitsazi, Rezvan and Biswas, Ansuman and Jiang, Chunjie and Zhao, Li and Tym, Joseph E and Brammer, Kevin M and Li, Jun and Shu, Zhigang and Maxwell, David S and Tacy, Jeffrey A and Mica, Ioan L and Darkoh, Michael and di Micco, Patrizio and Russell, Kaitlyn P and Workman, Paul and Al-Lazikani, Bissan},
title = {canSAR 2024—an update to the public drug discovery knowledgebase},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {D1},
pages = {D1287--D1294},
doi = {10.1093/nar/gkae1050}
}
EUVIMED